Strategic Partnership AustinPx recently expanded access to its KinetiSol technology through a collaboration with Thermo Fisher Scientific, signaling openness to tiered partnerships and distributor-like arrangements that can be leveraged to accelerate market reach and generate co-sell opportunities.

Award Validated The Accelerating Innovation Award for KinetiSol Technology at the 2024 CPHI Pharma Awards enhances credibility with potential clients and can be used to open conversations around cutting-edge ASD solutions and reduced development timelines.

Leadership Transition Recent leadership changes, including the appointment of a new president and CEO in early 2024, may indicate strategic pivots or refreshed go-to-market plans, presenting a window to engage with decision-makers about priority CDMO capabilities and partnership models.

CDMO Focus As a mid-sized CDMO specializing in formulation and manufacturing of poorly soluble APIs using KinetiSol technology, AustinPx targets developers seeking faster, greener, and more flexible manufacturing solutions, suggesting sales plays around accelerated timelines, improved bioavailability, and cost efficiency.

Scale & Revenue With reported revenue between $25M and $50M and a growing partner ecosystem, there is potential to propose expanded service scopes, capacity commitments, and multi-project collaborations to upsell additional development stages or larger manufacturing batches.